WallStSmart

Abbott Laboratories (ABT)vsLENSAR Inc (LNSR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 78116% more annual revenue ($45.13B vs $57.70M). LNSR leads profitability with a 50.9% profit margin vs 13.9%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

LNSR

Buy

53

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.0Quality: 6.0
Piotroski: 2/9Altman Z: -3.69
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued
LNSRSignificantly Overvalued (-85.1%)

Margin of Safety

-85.1%

Fair Value

$6.71

Current Price

$5.74

$0.97 premium

UndervaluedFair: $6.71Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

LNSR4 strengths · Avg: 9.8/10
Return on EquityProfitability
36.2%10/10

Every $100 of equity generates 36 in profit

Profit MarginProfitability
50.9%10/10

Keeps 51 of every $100 in revenue as profit

Operating MarginProfitability
49.2%10/10

Strong operational efficiency at 49.2%

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

LNSR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$67.78M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Revenue GrowthGrowth
-5.2%2/10

Revenue declined 5.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : LNSR

The strongest argument for LNSR centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 50.9% and operating margin at 49.2%.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : LNSR

The primary concerns for LNSR are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

ABT profiles as a value stock while LNSR is a declining play — different risk/reward profiles.

LNSR carries more volatility with a beta of 0.87 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 53/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

LENSAR Inc

HEALTHCARE · MEDICAL DEVICES · USA

LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.

Want to dig deeper into these stocks?